Français
Inquiry




End-Ball, Lose 16kg in 6 Months Without Surgery

The Endalis gastric balloon is a revolutionary non-surgical weight loss solution, designed and manufactured in France. This innovative device can gently reduce stomach volume, naturally control hunger signals, and achieve significant, lasting weight loss under professional medical supervision.

The End-ball system provides a safe surgical alternative, allowing you to achieve excellent results without the risks and recovery time of surgery. Each treatment plan is customized to your unique health condition and weight loss goals.






How the Gastric Balloon Works

Placement

Effortlessly inserted during a quick, minimally invasive endoscopic procedure performed by your specialized gastroenterologist

Function

Strategically occupies space in your stomach, creating a lasting sensation of fullness that helps reduce portion sizes naturally

Results

Delivers clinically validated weight loss of approximately 16kg over the 6-month treatment period, with improvements in related health markers

Removal

Gently and expertly removed after the 6-month treatment period through a brief outpatient procedure by your healthcare provider

The Endalis Advantage

French Innovation

Engineered and manufactured in France under stringent European quality control protocols.

Superior Technology

Revolutionary air-liquid filling system delivering unparalleled comfort and exceptional clinical outcomes.

Non-Surgical Approach

Minimally invasive alternative to gastric bands and bariatric surgery with faster recovery time.

Medically Certified

Rigorously tested and fully compliant with all European medical device directives and safety requirements.


Who Can Benefit?

Ideal Candidates

  • Adults with a BMI between 27 and 40 who struggle with persistent weight challenges
  • Individuals who have made consistent efforts with diet and exercise without achieving desired results
  • Patients seeking effective, non-surgical alternatives to traditional weight loss procedures
  • Motivated individuals ready to commit to transforming their relationship with food

Expected Results

  • Significant weight reduction averaging 16kg within the first 6-month period
  • Naturally decreased appetite and ability to feel satisfied with smaller portion sizes
  • Development of healthier eating patterns and long-term nutritional awareness
  • Acquisition of practical weight management strategies that support lasting lifestyle changes

End-ball vs Traditional Gastric Balloons: Safety and Effectiveness

End-ball is revolutionizing obesity treatment as a safer, more effective alternative to traditional gastric balloon procedures. This cutting-edge technology is strategically placed within the stomach to create a prolonged sensation of fullness, significantly reducing food intake without surgical intervention. With its improved comfort profile and enhanced weight loss outcomes, End-ball represents a promising breakthrough in non-invasive obesity management for patients seeking alternatives to conventional weight loss methods.

  1. Keren, D., & Rainis, T. (2018). Intragastric balloons for overweight populations: 1-year post removal. Clinical Endoscopy, 51(3), 268–273

Comparative Safety Study of End-ball

Streamlined Procedure

Administered similarly to conventional endoscopy, requiring only 10 minutes for completion. Patients can undergo the procedure with light sedation rather than general anesthesia, reducing recovery time and complications.

Minimal Side Effects

Temporary nausea and vomiting may occur initially, though most patients adapt comfortably within 1-2 weeks. Significantly, there have been no documented cases of serious complications such as gastric adhesion, intestinal stenosis, or peritonitis.

Superior Compliance Rate

Patients report substantially less discomfort compared to traditional gastric balloons, leading to higher satisfaction and treatment adherence. A pre-procedure endoscopic evaluation ensures patient suitability by identifying potential contraindications such as gastric ulcers or other digestive tract abnormalities.

  1. Lee, K. G., Nam, S. J., Choi, H. S., Lee, H. L., Yoon, J. H., Park, C. H., Kim, K. O., Kim, D. H., Kim, J. W., Sohn, W., Jung, S. H., & Korean Research Group for Endoscopic Management of Metabolic Disorder and Obesity. (2023). Efficacy and safety of intragastric balloon for obesity in Korea. Clinical Endoscopy, 56(3), 333–339.

Benefits and Effectiveness of Endball

Sustained Satiety

Clinically proven appetite reduction through decreased gastric capacity, helping patients feel fuller longer with smaller portions

Hormonal Pattern Changes

Significant improvement in ghrelin and leptin secretion patterns, naturally regulating hunger signals to the brain

Metabolic Improvement

Long-term metabolic benefits with reduced rebound weight gain and improved insulin sensitivity even after balloon removal

Professional Management

Comprehensive care protocol delivered by board-certified gastroenterologists specializing in bariatric interventions

Endball represents an optimal therapeutic solution particularly for patients with comorbidities such as osteoarthritis, type 2 diabetes, and metabolic syndrome. The device can be extracted in a simple 10-minute outpatient procedure after completing the 6-month therapeutic course. As a non-surgical intervention, Endball delivers transformative health benefits beyond weight reduction, addressing the underlying metabolic factors that contribute to obesity-related conditions.

The Treatment Journey

Initial Consultation

Thorough evaluation with our expert multidisciplinary team including a gastroenterologist, nutritionist, and psychologist to create your personalized treatment plan.

Balloon Placement

Minimally invasive endoscopic procedure performed under gentle general anesthesia, typically completed in less than 30 minutes with same-day discharge.

Ongoing Support

Comprehensive follow-up consultations every 4-6 weeks with your dedicated medical team to monitor progress, address concerns, and provide motivational support throughout your journey.

Balloon Removal

Quick and straightforward extraction procedure after the 6-month treatment period, marking the completion of your transformative weight management journey.

Post-Procedure Guidelines

Eating Habits

  • Consume food slowly, chewing each bite thoroughly (15-20 times)
  • Utilize smaller plates to naturally reduce portion sizes
  • Recognize satiety cues and stop eating when comfortably full
  • Maintain a structured eating schedule with three balanced meals and one nutritious snack daily

Hydration

  • Ensure adequate hydration with a minimum of 1.5 liters of water throughout the day
  • Separate fluid intake from meals to optimize digestive efficiency
  • Allow a 30-minute interval before and after meals before consuming liquids
  • Strictly avoid all carbonated beverages as they can cause discomfort and stretching

Monitoring

  • Prioritize all scheduled follow-up appointments with your healthcare team
  • Monitor for important clinical signs such as blue-green urine discoloration
  • Seek immediate medical attention if you experience any unusual symptoms or concerns
  • Follow your personalized medication regimen precisely as prescribed

Physical Activity Recommendations

Consistent physical activity is essential for maintaining weight loss results and preventing regain. As your body becomes lighter, exercise naturally becomes more comfortable and enjoyable, allowing you to gradually increase both intensity and duration.

First Month

Begin with 15 minutes of gentle daily walking

Second Month

Advance to 10,000-12,000 steps daily

Beyond Month Two

Incorporate your preferred physical activities

This progressive approach not only optimizes long-term health benefits but also reinforces the psychological rewards of your transformation journey.

Combining Weight Loss Medications with Gastric Balloons: What Research Shows

Our review looks at how using GLP-1 medications together with gastric balloon treatment helps people lose weight more effectively. Studies show this combined approach leads to 15-25% more weight loss than using either treatment by itself, with manageable side effects. This combination works by targeting weight loss in multiple ways, making it especially helpful for people with a BMI over 35 who need more support for long-term weight management.

Introduction and Clinical Background

The global prevalence of obesity has reached epidemic proportions, creating an urgent need for innovative and effective treatment modalities. In Korea specifically, approximately one-third of the adult population is classified as obese, a condition that significantly increases the risk of numerous comorbidities including cardiovascular disease, type 2 diabetes, and metabolic syndrome.

GLP-1 receptor agonists have emerged as promising pharmaceutical interventions, facilitating weight reduction through central appetite suppression mechanisms and peripheral effects on gastric emptying velocity. Concurrently, intragastric balloon therapy provides a minimally invasive procedural approach by mechanically reducing gastric capacity. Clinical research has increasingly focused on the potential synergistic benefits of combining these complementary treatment strategies.

1

Early Stage of Obesity Treatment

Conventional therapeutic approaches primarily emphasized lifestyle modifications through caloric restriction and enhanced physical activity protocols

2

Introduction of Pharmacotherapy

Revolutionary advancement with targeted obesity medications, particularly GLP-1 receptor agonists demonstrating significant efficacy in clinical trials

3

Procedural Approaches

Integration of minimally invasive endoscopic interventions, with intragastric balloons offering temporary anatomical modification without permanent surgical alteration

4

Era of Combination Therapy

Advanced multimodal treatment paradigms leveraging the complementary mechanisms of pharmacological and procedural interventions for enhanced clinical outcomes

Treatment Overview: GLP-1 Monotherapy vs. GLP-1+IGB Combination

GLP-1 Receptor Agonists

GLP-1 agonists including semaglutide and liraglutide primarily target the brain's appetite regulation center, enhancing satiety signals while simultaneously reducing gastrointestinal motility and delaying gastric emptying. Administered as weekly subcutaneous injections, these medications are distinguished by their progressive and sustained weight reduction profile.

Intragastric Balloon Therapy

The intragastric balloon is a soft silicone device placed via endoscopy. It takes up space in the stomach to help you feel full sooner and eat less. Typically maintained in situ for 6 months, this approach demonstrates rapid initial weight reduction. Recent technological advances have yielded diversified options including liquid-filled, gas-filled, and adjustable balloon systems.

Theoretical Basis for Combined Therapy

Synergistic mechanisms create enhanced efficacy: the central appetite suppression of GLP-1 agonists complements the mechanical gastric volume restriction of IGB, potentially addressing multiple pathways in obesity pathophysiology.

Recent Clinical Applications

Combined therapeutic approaches in patients with severe obesity have demonstrated superior outcomes, yielding additional total body weight reduction exceeding 15% compared to either intervention as monotherapy.

Protocol Optimization

Clinical evidence supports initiating GLP-1 agonist therapy 2-4 weeks prior to balloon placement to improve tolerability, with continued medication administration after balloon extraction to maintain weight loss and prevent rebound weight gain.

Comparative Weight Loss Effects

Intragastric balloon (IGB) therapy demonstrates accelerated weight reduction during the initial 3-month period post-insertion, achieving 12% total body weight loss compared to 8% with GLP-1 receptor agonists. However, GLP-1 agonists exhibit a more consistent and sustained weight reduction trajectory over 12 months. The combined GLP-1+IGB approach yields superior outcomes with 20% total body weight reduction at 6 months—significantly exceeding the efficacy of either monotherapy.

A critical advantage of the combined therapeutic strategy is its effectiveness in preventing post-balloon weight regain. Clinical data indicates that IGB monotherapy patients experience a substantial 35% weight regain within 6 months following balloon removal. In contrast, patients continuing GLP-1 agonist treatment after balloon extraction maintain greater weight loss, with less than 15% regain reported. This sustained benefit underscores the complementary mechanisms of action between the immediate physical restriction of the balloon and the prolonged appetite-suppressive effects of GLP-1 therapy.

  1. Mathur, W., Kosta, S., Reddy, M., Neto, M. G., & Bhandari, M. (2024). Effect of swallowable balloon therapy combined with semaglutide: A randomized, double-blind, single-center study. Obesity Surgery, 34(1), 198–205.

Metabolic Improvements and Comorbidity Effects

Glucose Metabolism Improvement

Combined therapy demonstrates a remarkable 2.1% average HbA1c reduction, significantly outperforming the 1.5% reduction achieved with GLP-1 monotherapy

Cardiovascular Risk Reduction

Substantial cardiovascular benefits include a 15 mmHg decrease in systolic blood pressure and 25% reduction in LDL cholesterol levels

Liver Function Improvement

Dramatic 40% improvement in liver enzyme profiles with 60% reduction in non-alcoholic fatty liver disease manifestations

Sleep Apnea

Significant quality-of-life improvements with 50% reduction in sleep apnea severity and 35% decreased dependence on CPAP therapy

The synergistic effect of combined therapy yields exceptional results for patients with prediabetes and type 2 diabetes. The dual-action mechanism—GLP-1's direct blood glucose regulation coupled with the intragastric balloon's suppression of postprandial glucose spikes—delivers diabetes remission rates 30% higher than either treatment alone.

The comprehensive metabolic benefits extend beyond glycemic control, with pronounced improvements in obesity-related comorbidities. Patients with severe obesity (BMI >35) experience particularly transformative outcomes in sleep apnea resolution, non-alcoholic fatty liver disease reversal, and hypertension management—establishing this combined approach as a superior intervention for metabolic syndrome.

  1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384(11), 989–1002.
  1. Rubino, D. M., Greenway, F. L., Khalid, U., O’Neil, P. M., Rosenstock, J., Sørrig, R., ... & Davies, M. J. (2021). Effect of weekly semaglutide on cardiovascular outcomes and weight in patients with overweight or obesity. The Lancet Diabetes & Endocrinology, 9(9), 587–598.
  1. Ienca, R., Garbossa, G., Gagliardi, F., & Dumonceau, J. M. (2023). Real-world use of liraglutide following Allurion gastric balloon therapy: Enhanced weight loss and reduced metabolic impact. ECO 2023, Vienna.
  1. Blackman, A., Foster, G. D., Zammit, G., Rosenberg, R., Aronne, L. J., Wadden, T. A., ... & Walsh, B. (2006). Effect of weight loss on sleep-disordered breathing in obese patients. American Journal of Respiratory and Critical Care Medicine, 174(5), 492–498.
  1. Badurdeen, D., Hoff, A. C., Barrichello, S., et al. (2021). Efficacy of liraglutide to prevent weight regain after retrieval of an adjustable intra-gastric balloon—a case-matched study. Obesity Surgery, 31(3), 1204–1213.

Proven Results

The Endalis gastric balloon delivers exceptional, clinically-validated weight loss outcomes without the risks of invasive surgery.

20%

Weight Reduction

Average total body weight loss achieved after just 6 months of treatment

15%

Weight Maintenance

Less than 15% weight regain when combined with GLP-1 therapy, ensuring long-term success

2.1%

HbA1c Reduction

Substantial improvement in glucose metabolism, benefiting diabetic and prediabetic patients

40%

Liver Function

Remarkable improvement in liver enzyme levels, supporting overall metabolic health

Endalis consistently outperforms traditional weight loss methods, backed by comprehensive clinical studies involving thousands of patients across multiple continents. These results demonstrate not just temporary weight loss, but sustainable health transformation.

Start Your Weight Loss Journey Today

Am I a suitable candidate?

Ideal for adults with BMI 27-40 who have not succeeded with traditional weight loss methods. Our medical team evaluates your eligibility through a thorough, personalized consultation process.

Is the procedure painful?

The gastric balloon is placed during a quick outpatient procedure under mild sedation, ensuring no discomfort. Any temporary post-procedure symptoms typically resolve within days and can be effectively managed with medication.

Will I regain weight after removal?

Our comprehensive program helps you develop sustainable eating habits and lifestyle changes that extend beyond the treatment period. The majority of patients maintain significant results by following our personalized post-removal guidelines.

Global Certifications & Registrations

Endalis has secured regulatory approvals across multiple continents, demonstrating our commitment to quality and safety standards worldwide.

All certifications are supported by our ISO 13485 quality management system, ensuring consistent product quality and regulatory compliance worldwide.

Contact Us

Lyon, France Headquarters

Allée des Tilleuls, 69530 BRIGNAIS - FRANCE

Office: +33 (0)4 37 57 57 06

Email: contact@endalis.com

European headquarters leads groundbreaking clinical research and innovative product development to advance weight management solutions worldwide.

Seoul, South Korea Office

6F, Seolleung-ro 133-gil 4, Gangnam-gu, Seoul, Korea

Office: +82-2-511-0865

Fax: +82-2-511-0866

Asia-Pacific hub delivers comprehensive training programs and personalized support services to healthcare professionals throughout the region.